ATAD2 (E8Y2K) Rabbit mAb #78568
- WB
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 180 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:200 - 1:800 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu910 of human ATAD2 protein.
Background
ATPase family AAA domain containing protein 2 (ATAD2) is an oncogenic protein that was originally identified as a coactivator for estrogen receptor (ESR1), and later identified as a coactivator for other transcription factors including c-Myc and E2F1, E2F2, and E2F3 proteins (1-4). ATAD2 is highly expressed and associated with poor prognosis in many types of cancer, including breast, uterine, colon, ovarian, stomach, non-small cell lung carcinoma, osteosarcoma, and cervical cancer (1,5-14). In cancer cells, overexpressed ATAD2 interacts with transcription factors and chromatin modifier proteins to induce the expression of genes that promote cell proliferation and inhibit apoptosis, ultimately promoting tumor growth (15,16). Indeed, knockdown of ATAD2 in pancreatic cancer cell lines has been shown to promote apoptosis, limit cell migration and invasion, and inhibit anchorage-independent growth (17). ATAD2 is a member of the ATPases associated with various cellular activities (AAA) family of proteins and contains a functional AAA domain in its central region, as well as a bromodomain near the C-terminus. The bromodomain binds to acetylated lysine residues on histone proteins, targeting ATAD2 protein to areas of active transcription, where it modulates chromatin structure and recruits additional transcription factors (18,19). Current efforts are underway to better characterize and develop inhibitors to the ATAD2 bromodomain for the treatment of various cancers (16,20-23).
- Zou, J.X. et al. (2007) Proc Natl Acad Sci U S A 104, 18067-72.
- Zou, J.X. et al. (2009) Cancer Res 69, 3339-46.
- Revenko, A.S. et al. (2010) Mol Cell Biol 30, 5260-72.
- Ciró, M. et al. (2009) Cancer Res 69, 8491-8.
- Wang, Y. et al. Lancet 365, 671-9.
- Teschendorff, A.E. et al. (2006) Genome Biol 7, R101.
- Fellenberg, J. et al. (2007) Mod Pathol 20, 1085-94.
- Petroziello, J. et al. (2004) Oncogene 23, 7734-45.
- De Angelis, P.M. et al. (2006) Mol Cancer 5, 20.
- Zheng, L. et al. (2015) Oncol Rep 33, 2337-44.
- Fouret, R. et al. (2012) Clin Cancer Res 18, 5606-16.
- Wan, W.N. et al. (2014) Asian Pac J Cancer Prev 15, 2777-83.
- Wu, G. et al. (2014) BMC Cancer 14, 107.
- Zhang, M. et al. (2016) Clin Transl Oncol 18, 776-81.
- Caron, C. et al. (2010) Oncogene 29, 5171-81.
- Boussouar, F. et al. (2013) Biochim Biophys Acta 1829, 1010-4.
- Liu, N. et al. (2019) Oncol Lett 17, 3489-94.
- Morozumi, Y. et al. (2016) J Mol Cell Biol 8, 349-62.
- Koo, S.J. et al. (2016) Oncotarget 7, 70323-35.
- Gay, J.C. et al. (2019) Proteins 87, 157-67.
- Hussain, M. et al. (2018) Expert Opin Ther Targets 22, 85-96.
- Bamborough, P. et al. (2018) J Med Chem 61, 8321-36.
- Zhou, Y. et al. (2018) Phys Chem Chem Phys 20, 23222-32.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.